Pharmacokinetics of isoniazid in 30 tuberculosis patients in Abidjan, Cte dIvoire

Abstract

Isoniazid is a major component in tuberculosis (TB) treatment, which is often used in combination or alone as prophylaxis for its high efficiency on bacilli of Mycobacterium tuberculosis. It is responsible for an increased risk of developing serious liver side effects involving the prognosis of the patient. Its coinfection with HIV is currently a real public health problem. The purpose of this study was to establish the pharmacokinetic profile of isoniazid in Ivorian patients infected with TB taking a combination containing isoniazid at Abidjan. A cross-sectional analytical and descriptive study on the pharmacokinetics of isoniazid in 30 adults Ivorian patients on TB treatment was conducted. Blood samples at intervals of time were performed by high performance liquid chromatography-ultra violet (HPLC-UV). 30 adult patients were enrolled, with sex ratio M/F=2. Mean age was 38.67 (18 to 67 years). 56 (7%) were slow acetylators. 14 (46.7%) were treated for pulmonary TB smear negative and 36.67% had a co-infection TB/HIV. A positive correlation was also observed between body mass index (BMI) and Vd (0.444 and p=0.14) and a negative correlation between BMI and Tmax (-0.399, P=0.29). The main biological variable influencing pharmacokinetic parameters according to the analysis is the acetylation profile of the patient.